Endothelin receptor antagonist bosentan role in modern strategy for patients with pulmonary arterial hypertension treatment
https://doi.org/10.26442/2075-082X_2018.2.66-71
Abstract
About the Authors
O. A. ArkhipovaRussian Federation
T. V. Martynyuk
Russian Federation
References
1. Galiè N, Humbert M, Vachiery J.L et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2015; 46: 903-75.
2. Клинические рекомендации. Легочная гипертензия 2016 г. http://cr.rosminzdrav.ru/ schema.html?id=136#/text.
3. Легочная гипертензия. Под ред. И.Е.Чазовой, Т.В.Мартынюк. М.: Практика, 2015.
4. Дремина Н.Н., Шурыгин М.Г., Шурыгина И.А. Эндотелины в норме и патологии. Междунар. журн. прикладных и фундаментальных исследований. 2016; 10: 210-4.
5. Channick R.N, Simonneau G, Sitbon O et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 6 (358): 1119-23.
6. Rubin L.J, Badesch D.B, Barst R.J et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 34: 6896-903.
7. Galiè N, Hinderliter A.L, Torbicki A. et al. Effects of the Oral Endothelin-Receptor Antagonist Bosentan on Echocardiographic and Doppler Measures in Patients With Pulmonary Arterial Hypertension. J Am Coll Cardiol 2003; 41:1380-6.
8. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Scientific_Discussion/human/ 000401/WC500041457.pdf
9. Мартынюк Т.В., Наконечников С.Н., Чазова И.Е. Антагонисты рецепторов эндотелина при легочной артериальной гипертензии: вчера, сегодня, завтра. Рос. кардиол. журн. 2009; 4 (78): 73-81.
10. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000401/WC500041455.pdf
11. Galiè N, Beghetti M, Gatzoulis M.A et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006; 114 (1): 48-54.
12. Sitbon O, Gressin V, Speich R et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 170 (11): 1212-7.
13. Jaïs X, D'Armini A.M, Jansa P et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol 2008; 52 (25): 2127-34.
14. Hughes R.J, Jais X, Bonderman D et al. The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study. Eur Respir J 2006; 28 (1): 138-43.
15. Galiè N, Rubin Lj, Hoeper M et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371 (9630): 2093-100.
16. McLaughlin V.V, Sitbon O, Badesch D.B et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005; 25: 244-9.
17. Provencher S, Sitbon O, Humbert M et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 2006; 27 (5): 589-95.
18. Humbert M, Barst R.J, Robbins I.M et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHEE-2. Eur Respir J 2004; 24 (3): 353-9.
19. McLaughlin V, Channick R.N, Ghofrani H.A at al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J 2015; 46: 405-13.
20. McLaughlin V.V, Oudiz R.J, Frost A et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006; 174 (11): 1257-63.
21. McLaughlin V.V, Archer S.L, Badesch D.B et al. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. Am Coll Cardiol 2009; 53: 1573-619.
22. Архипова О.А., Мартынюк Т.В., Лазуткина В.К. и др. Применение неселективного антагониста рецепторов эндотелина при идиопатической легочной гипертензии. Терапевт. архив. 2010; 82 (11): 70-3.
Review
For citations:
Arkhipova O.A., Martynyuk T.V. Endothelin receptor antagonist bosentan role in modern strategy for patients with pulmonary arterial hypertension treatment. Systemic Hypertension. 2018;15(2):66-71. https://doi.org/10.26442/2075-082X_2018.2.66-71
Email this article 